[HTML][HTML] Liver fibrosis: therapeutic targets and advances in drug therapy
Z Tan, H Sun, T Xue, C Gan, H Liu, Y Xie… - Frontiers in cell and …, 2021 - frontiersin.org
Liver fibrosis is an abnormal wound repair response caused by a variety of chronic liver
injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and …
injuries, which is characterized by over-deposition of diffuse extracellular matrix (ECM) and …
Epigenetic regulation in fibrosis progress
T Xue, X Qiu, H Liu, C Gan, Z Tan, Y Xie, Y Wang… - Pharmacological …, 2021 - Elsevier
Fibrosis, a common process of chronic inflammatory diseases, is defined as a repair response
disorder when organs undergo continuous damage, ultimately leading to scar formation …
disorder when organs undergo continuous damage, ultimately leading to scar formation …
[HTML][HTML] Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro
C Gan, Y Wang, Z Xiang, H Liu, Z Tan, Y Xie… - Journal of Advanced …, 2023 - Elsevier
Introduction Idiopathic pulmonary fibrosis (IPF), a life-threatening interstitial lung disease, is
characterized by excessive activation and proliferation of fibroblasts and epithelial-…
characterized by excessive activation and proliferation of fibroblasts and epithelial-…
[HTML][HTML] Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study
…, Q Zhang, H Liu, G Wang, L Wang, Y Li, Z Tan… - Respiratory …, 2022 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a serious interstitial lung disease with a
complex pathogenesis and high mortality. The development of new drugs is time-consuming …
complex pathogenesis and high mortality. The development of new drugs is time-consuming …
Cryptotanshinone reverses the epithelial‐mesenchymal transformation process and attenuates bleomycin‐induced pulmonary fibrosis
…, C Gan, H Liu, L Wang, Y Li, Z Tan… - Phytotherapy …, 2020 - Wiley Online Library
Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial pneumonia that causes pulmonary
tissue damage and functional impairment. To investigate the effects of cryptotanshinone on …
tissue damage and functional impairment. To investigate the effects of cryptotanshinone on …
Erbin is required for myelination in regenerated axons after injury
C Liang, Y Tao, C Shen, Z Tan, WC Xiong… - Journal of …, 2012 - Soc Neuroscience
Neuregulin 1 (NRG1) is an axon-derived factor that is critical for Schwann cell (SC)
development and myelinogenesis in a manner dependent on transmembrane tyrosine kinases …
development and myelinogenesis in a manner dependent on transmembrane tyrosine kinases …
A novel multikinase inhibitor SKLB‐YTH‐60 ameliorates inflammation and fibrosis in bleomycin‐induced lung fibrosis mouse models
…, L Yue, Z Liu, W Wei, X Su, Q Zhang, Z Tan… - Cell …, 2021 - Wiley Online Library
Objectives Idiopathic pulmonary fibrosis (IPF) is marked by the excessive accumulation of
extracellular matrix, which participates in a variety of chronic diseases or injuries and seriously …
extracellular matrix, which participates in a variety of chronic diseases or injuries and seriously …
Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis
X Su, Z Tan, G Wang, Z Liu, C Gan, L Yue, H Liu… - European Journal of …, 2023 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized with high mortality,
unknown etiology, and lack of effective treatment. Many evidences validate that inhibiting the …
unknown etiology, and lack of effective treatment. Many evidences validate that inhibiting the …
Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents
L Yue, T Xue, X Su, Z Liu, H Liu, Z Tan, C Gan… - European journal of …, 2022 - Elsevier
Liver fibrosis is characterized by the excessive deposition of extracellular matrix components
and results from chronic liver injury. At present, there is no approved drug for the treatment …
and results from chronic liver injury. At present, there is no approved drug for the treatment …
An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF‐β1 signalling
T Xue, L Yue, G Zhu, Z Tan, H Liu, C Gan… - Liver …, 2023 - Wiley Online Library
Background and Aims Liver fibrosis is an excessive wound‐healing response governed by
activated hepatic stellate cells (HSCs). To date, there is no drug available for liver fibrosis. …
activated hepatic stellate cells (HSCs). To date, there is no drug available for liver fibrosis. …